Astellas Pharma Inc.

Business, technology & evidence

• Leadership as of October 2026Astellas' official leadership page lists Kenji Yasukawa as Representative Director and Chairman of the Board, and Naoki Okamura as Representative Director, President and CEO.
• FY2025 group basisAstellas' live overview states that it is headquartered in Tokyo, operates in more than 70 countries and areas, and recorded FY2025 global revenue of ¥2,139.2 billion (also shown as US$14.17 billion on the page). This is group-level global revenue.
• An April 2026 announcement reports first dosing in Phase 3 setidegrasib/ASP3082 for pancreatic cancer. A Japanese official registry also records first dosing in NSCLC Phase 3 in August 2026.
• The flagship protein degrader is an internally developed KRAS G12D program; a separate Cullgen collaboration also exists.
• The original 2025 discovery paper resolves the KRAS(G12D)/ASP3082/VHL ternary complex, supporting VHL-dependent proteasomal degradation.
• An original March 2026 NEJM Phase 1 study included 203 patients and reported weekly intravenous dosing, safety, and antitumor activity. It is not used for direct cross-study ranking.
• Astellas Pharma is a Japan-headquartered pharmaceutical company engaged in research, development, manufacturing and commercialization of prescription medicines. Its global operations combine pharmaceutical discovery with clinical development and external research partnerships. The company's therapeutic interests include oncology, transplantation and selected specialty diseases, and its development work spans small molecules and advanced therapeutic technologies. Astellas is based in Tokyo and its shares are listed on the Tokyo Stock Exchange under code 4503.
• SecuritiesTSE: 4503